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Abstract
Background: About 30-50% of Hodgkin lymphomas (HLs) harbor the Epstein-Barr virus (EBV), but the impact of
EBV infection on clinical outcomes has been unclear. EBV-encoded small RNAs (EBERs) are presented in all EBV-
infected cells, but their functions are still less understood.
Results: EBER1 was transfected into two HL cell lines, KMH2 and L428, and microarrays were used to screen for
EBER1-induced changes. We found that EBER1 suppressed p21
cip1/waf1 transcription in HL cell lines. In addition,
positive regulators of p21
cip1/waf1 transcription, such as p53, EGR1, and STAT1, were decreased. Suppression of
p21
cip1/waf1 in the EBER1
+ HL cell lines was associated with increased resistance to histone deacetylase inhibitors or
proteasome inhibitors, drugs known to cause apoptosis by increasing p21
cip1/waf1 levels. On biopsy specimens, EBV
+ HLs had weaker expression of both p21
cip1/waf1 and active caspase 3. Clinically, suppression of p21
cip1/waf1 in EBV
+
HLs was associated with a worse 2-year disease-free survival rate (45% for EBV
+ HLs vs. 77% for EBV
- HLs, p =
0.002).
Conclusion: Although the underlying mechanisms are still relatively unclear, EBER1 inhibits p21
cip1/waf1 transcription
and prevents apoptosis through down-regulation of p53, EGR1, and STAT1. The anti-apoptotic activity of EBER1
may be important in the rescue of Reed-Sternberg cells from drug-induced apoptosis and in the clinical behaviors
of EBV
+ HLs.
Background
In industrialized countries, about 30-50% of Hodgkin
lymphomas (HLs) have been associated with the
Epstein-Barr virus (EBV), but the impact of EBV infec-
tion on the clinical outcomes has been difficult to mea-
sure, because most HLs respond well to chemotherapy.
In a multicenter retrospective survey, the prognosis was
found to be worse for adult EBV
+ HLs than for their
EBV
- counterparts [1]. However, the underlying
mechanism is still unknown.
In addition to HL, EBV is also associated with Bur-
kitt’s lymphoma, nasopharyngeal carcinoma, and other
malignancies [2]. Although EBV can switch its life cycle
between a lytic phase and a latent phase [3], the virus
exists only in a latent phase in EBV-infected tumor
cells. The latent phase is characterized by the variable
expression of a limited set of virus-encoded genes,
including 6 nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C, &
LP), 3 latent membrane proteins (LMPs 1, 2A, 2B), and
2 small homologous RNAs (EBERs 1& 2). Depending on
the expression patterns, the latent phase can be further
classified into three types [4]. EBNA1 and EBERs are the
only EBV-encoded genes common to all latencies. They
are probably indispensable for latency maintenance or
malignant transformation.
In the latency phase, EBNA1 maintains replication of
the episomal form of the virus [5], and it enhances the
growth of HL cells [6]. In contrast, the roles of EBERs
are unclear and controversial. EBER probably interacts
with both a ribosomal protein L22 and an RNA-depen-
dent protein, PKR [7]. According to one model, PKR
may induce apoptosis; EBERs antagonize PKR-mediated
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binding and abolishes the anti-apoptotic activity of
EBERs. The anti-apoptotic activity of EBERs is consis-
tent with the finding that EBV infection could reduce
apoptosis in Burkitt’s lymphoma [8,9]. In addition, PKR-
independent anti-apoptotic activities of EBERs have
been reported [10], but the mechanism and clinical sig-
nificance are still unknown.
To address the mechanism and clinical significance of
the anti-apoptotic activity of EBERs,w ea n a l y z e dt h e
EBER1-induced changes in HL cell lines using microar-
rays and found that EBER1 suppressed p21
cip1/waf1 tran-
scription. p21
cip1/waf1 is also known as the cyclin-
dependent kinase inhibitor 1A (CDKN1A), and it nor-
mally causes cell cycle arrest at the G1/S phase, and
induces or inhibits apoptosis [11-13]. We demonstrated
that decreased p21
cip1/waf1 transcription is associated
with increased resistance to drug-induced apoptosis in
HL cell lines. Most significantly from a clinical perspec-
tive, suppression of p21
cip1/waf1 and the increased resis-
tance to drug-induced apoptosis are associated with a
worse prognosis in cases of EBV
+ HLs.
Methods
Cell lines
KMH2 and L428, two EBV-negative HL cell lines, were
obtained from the German Collection of Microorgan-
isms and Cell Culture (DSMZ, Braunschweig, Germany).
Similar to the classical Reed-Sternberg cells in HLs,
these cell lines are CD30
+/CD15
+/CD3
-/CD19
-, and they
have rearrangement of the immunoglobulin heavy-chain
genes [14]. These cell lines were cultured in RPMI1640
containing 10% fetal bovine serum, 50 μg/mL strepto-
mycin, and 50 U/mL penicillin, at 37°C with 5% CO2.
Construction of plasmids expressing EBER1 or antisense-
EBER1 and selection of stable clones
The plasmid p9362 with an H1 promoter for transcrip-
tion of small RNAs was used as the expression vector.
The plasmid also expressed EGFP, as well as Kanamycin
in bacteria or G-418 in eukaryocytes. The 167-nucleo-
tide EBER1 or antisense-EBER1 was inserted into p9362
for construction of p9362-EBER1 or p9362-antisense-
EBER1. Four cell lines were constructed: KMH2 trans-
fected with p9362-EBER1 (KE), L428 transfected with
p9362-EBER1 (LE), KMH2 transfected with p9362 (K9),
L428 transfected with p9362 (L9). One additional con-
trol cell line, KMH2 transfected with p9362-antisense-
EBER1 (K-anti-E), was also established.
Briefly, about 1 × 10
6 KMH2 or L428 cells were trans-
fected with 30 μg EBER1-expressing plasmid (p9362-
EBER1), antisense-EBER1-expressing plasmid (p9362-
antisense-EBER1), or control plasmid (p9362) by electro-
poration with an ECM630 system (BTX, Holliston, MA).
Stable clones were selected in RPMI1640 and 10% fetal
bovine serum containing 1 mg/mL GENETICIN (Invi-
trogen, Carlsbad, CA). EBER1
+ cell lines (KE & LE), an
antisense-EBER1
+ cell line (K-Anti-E), and plasmid-only
cell lines (K9 & L9) were established. A purity of greater
than 99% of EGFP
+ cells was confirmed by flow cyto-
metric analysis and expression of EBER1 was confirmed
by Northern blotting.
Northern blotting
Northern blotting was done with dig-labeled probes: 5’-A
CAGACACCGTCCTCACCACCCGGGACTTGTACCC
GGGACGGGTG-3’ for EBER1 or 5’-TCTTCTCTG
TATCGTTCCAATTTTAGTATATGTGCTGCCG-3’ for
U6.
Briefly, 2.5 μg small RNAs were separated on a 5%
denaturing polyacryamide gel and transferred to a
Hybond-N membrane (Amersham, Little Chalfont,
Bucks, UK). The membrane was hybridized with the
EBER1 or U6 probe at a concentration of 50 ng/mL in a
buffer containing 50% formamide at 52°C for 16 hours.
The membrane was then washed twice with 2 × SSC in
0.1% SDS at 25°C for 5 min, and twice with 0.2 × SSC
in 0.1%SDS at 68°C for 10 min. Anti-digoxigenin-AP
and CSPD (Roche, Mannheim, Germany) were used for
development of chemiluminescence.
Microarray
The Affymetrix chip, Human Genome U133 plus 2.0,
was used to obtain genome-wide transcriptional profiles
of the four stable cell lines (K9, KE, L9, and LE). First-
strand cDNAs were synthesized from 10 μgo ft o t a l
RNAs with a T7-promoter-oligo (dT) primer. After sec-
ond-strand synthesis, biotin-labeled cRNAs were tran-
scribed from the T7 promoter. The cRNAs were
fragmented into sizes ranging from 35 to 200 nucleo-
tides, labeled with streptavidin-PE, mixed with control
RNAs (bioB, bioC, bioD, and cre), and hybridized with
the glass slides according to the GeneChip Expression
Analysis Technical Manual from Affymetrix. The arrays
were scanned with GenePix 4000B (Molecular Devices,
Sunnyvale, CA, USA), and the data were extracted with
Affymetrix Microarray Suite (MAS) software and sub-
mitted to Gene Expression Ominbus at http://www.ncbi.
nlm.nih.gov/geo/ with the accession number GSE12427.
Local normalization of the extracted raw data was
done online at http://pevsnerlab.kennedykrieger.org/sno-
madinput.html[15]. In this method, the significance of
the difference between the EBER1
+ cell lines and the
control cell lines was designated by the z-score. For
example, the p21
cip1/waf1 transcripts had a 2-fold
decrease from 2260 in K9 to 1164 in KE, a mean level
of 1712, and a z-score, ZK, of - 2.5. The z-score meant
t h a tt h e2 - f o l dd e c r e a s ef o rp21
cip1/waf1 was located at
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to the changes of genes with a similar mean level of
expression. Each gene thus had a ZK for KE vs.K 9 ,a n d
as e c o n dZ L for LE vs. L9. The changes for the gene
were concordant if both z-scores were positive or both
z-scores were negative.
RT-PCR for p21
cip1/waf1 splicing variants
Eight splicing variants of p21
cip1/waf1 have been reported:
variant 1, variant 2, Alt-a, Alt-a’,A l t - b ,A l t - c ,B ,a n dC
[16,17]. A universal RT primer, 5’-RS-CATTAGCGCAT
CACAGTCGC-3’ (5506-5487), was used for converting
mRNAs of all splicing variants into cDNAs. This RT pri-
mer consists of a p21
cip1/waf1 binding sequence tagged
with a random sequence (RS): 5’-GTATACTGCAGGG
TCTGATAC-3’. A fluorescent universal reverse PCR
primer, 5’-FAM-ATAGGTATACTGCAGGGTCTGAT
AC-3’, and a forward PCR primer specific for each var-
iant were then used to amplify the cDNAs. The specific
forward primers were: 5’-CTGCCGAAGTCAG
TTCCTTG-3’ (variant 1, 18~37), 5’-ACTCAGAGGA
GGTGAGAGAG-3’ (variant 2, 79~98), 5’-GGTG
GCTATTTTGTCCTTGG-3’ (Alt-a, a’ and b, - 835~-
814), 5’-GGAGGCAAAAGTCCTGTGTT-3’ (Alt-c,
- 2219~-2197), 5’-AAGGAGGAGAGAGACCCT CT-3’
(B, 5266~5286), and 5’-CTAGAAAATCCAGTTG
CTG-3’ (C, 3954~3972). RT-PCR for b2M was used as
an internal control. A reverse primer, 5’-RS-CAG
AATTTGGAATTCATCCAA-3’,a n daf o r w a r dp r i m e r ,
5’-CTTTGTCACAGCCCAAGATAG-3’,w e r eu s e d .T h e
numbers in parentheses are the locations of the primers,
with respect to the genomic position of the p21
cip1/waf1,
with the transcription start site of variant 1 being +1.
The PCR products were separated by high-resolution
capillary electrophoresis and quantified by fluorescence.
T h es i z eo ft h eP C Rp r o d u c t si nb a s ep a i r sw e r e :2 1 6
for variant 1, 296 for variant 2, 179 for alt-a, 225 for alt-
a’, 191 for alt-b, 349 for alt-c, 208 for B, and 213 for C.
The 3 variants (alt-a, a’ a n db )f r o mt h es a m eP C Rh a d
different sizes due to alternative splicing.
Real-time RT-PCR for p21
cip1/waf1
Taqman® Gene Expression Assays (Applied Biosystems,
Foster City, CA) were used for real-time RT-PCR of
p21
cip1/waf1 (HS_0001121172_m1) and actin
(HS_00357333_g1). Total RNAs were extracted from
K9, KE, L9, and LE cells. The RNAs were reverse tran-
scribed into cDNAs with random hexamers. After an
initial 10-min denaturation step at 95°C, 45 cycles of
PCR were performed with denaturation at 95°C for 15
sec and annealing at 60°C for 1 min on the Stepone™
Real-Time PCR system (Applied Biosystems, Foster City,
CA). The threshold cycle of p21
cip1/waf1 minus that of
actin was calculated.
Western blotting for p21
cip1/waf1, EGR1, STAT1, p53, SirT5,
GAPDH, cyclin-dependent kinases (CDKs) and cyclins
Western blotting was performed with the following anti-
bodies: p21
cip1/waf1 (clone CP74, Lab Vision, Fremont,
CA), SirT5 (rabbit polyclonal, Abcam, Cambridge, UK),
STAT1 (clone 42H3, Cell signaling, Danvers, MA),
EGR1, p53, CDK6, and GAPDH (clone 588, clone DO-
1, clone C-21, and clone FL-335, SANTA CRUZ, Santa
Cruz, CA), CDK1, CDK2, CDK4, and cyclin B1 (clone
POH-1, clone Poly6332, clone Poly6333, and clone
Poly6334, Biolegend, San Diego, CA), cyclin A (clone
25/CyclinA, BD Pharmingen, Franklin Lakes, NJ), cyclin
D2, and cyclin E (clone DCS-3.1, and clone HE12,
Abcam, Cambridge, UK).
Cell cycle analysis
Cells were cultured in RPMI1640 medium plus 10% fetal
bovine serum for 24 hours. The cells were fixed with
75% ethanol at -20°C overnight and were stained in 50
μg/mL propidium iodide (Sigma, Saint Louis, MO,
USA), 0.05% Triton X-100, 0.1 μg/μLR N a s eA ,a n d1 ×
PBS at 37°C for 30 min in the dark. The stained cells
were washed with 3 mL PBS and suspended in 500 μL
PBS for flow-cytometric analysis.
Apoptosis induced by TSA & MG115 measured by flow
cytometry for Annexin V and propidium iodide
TSA (Trichostatin A, a histone deacetylase inhibitor from
Sigma, Saint Louis, MO, USA) and MG115 (a protea-
some inhibitor from Calbiochem, San Diego, CA) were
used to induce apoptosis through up-regulation of
p21
cip1/waf1. About 1 × 10
5 KE, K9, LE, or L9 cells were
grown in 1 mL of medium containing by 0.5 μMT S Ao r
by 0.4 μM MG115. After 2 days, the cells were harvested,
washed twice with 1× PBS, and suspended in 100 μL1 ×
binding buffer containing 10 mM Hepes at pH 7.4, 140
mM NaCl, and 2.5 mM CaCl2. The cells in 100 μLb i n d -
ing buffer were mixed with 5 μL APC-conjugated
Annexin V (BD Pharmingen, Franklin Lakes, NJ) and 5
μLo f5 0μg/mL propidium iodide at 25°C for 15 min.
The stained cells were diluted with 400 μLo f1 ×b i n d i n g
buffer and analyzed by flow cytometry within 1 hour.
Induction of p21
cip/waf1 by TSA or MG115
measured by ELISA
K9, KE, L9, LE cells were treated with 0.5 μMT S Ao r
0.4 μM MG115 for 1 day. Untreated cells were used as
controls. The amounts of p21
cip/waf1 were measured
with an ELISA kit (Total p21
cip/waf1 Sandwich ELISA
Kit, Cell Signaling, Danvers, MA). The ratio of p21
cip/
waf1 in the treated cells to that in the untreated cells was
calculated.
Briefly, after cell lysis and protein extraction, 25 μg
proteins were loaded onto p21
cip/waf1 antibody-coated
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p21
cip/waf1, an HRP-linked secondary antibody, and the
TMB substrate were applied sequentially. The absor-
bance at 450 nm was measured, and the background
absorbance was subtracted out. The ratios of the absor-
bances of treated cells to those of untreated cells were
calculated.
Cell growth curve
For growth curve, 1 × 10
4 K9, KE, L9, or LE cells were
grown in 0.5 mL medium containing 0 to 0.5 μMT S A
or 0 to 0.4 μM MG115 for up to 2 days. The cells were
stained with 0.4% trypan blue and counted by
hemocytometer.
Tissue samples
Biopsy specimens of 94 HLs with sufficient tissues and
clinical data for further investigations were retrieved
from the lymphoma database at the Department of
Pathology of the National Taiwan University Hospital.
The study was approved by the ethics committee of the
National Taiwan University Hospital.
Immunohistochemistry for p21
cip1/waf1 and in situ
hybridization for EBER1
Immunoperoxidase stain for p21
cip1/waf1, active caspase
3, and Ki-67 were performed on sections of formalin-
fixed, paraffin-embedded HL cell blocks and tissue sam-
ples with the antibodies to p21
cip1/waf1 (clone EA10, Cal-
biochem, Darmstadt, Germany), active caspase 3 (C92-
605, BD Pharmingen, Franklin Lakes, NJ), and Ki67
(MIB-1, DAKO, Glostrup, Denmark). For each case, 50
Reed-Sternberg cells were examined, and the percen-
tages of positive cells were recorded.
In situ hybridization for EBER1 was done on formalin-
fixed, paraffin-embedded tissue sections with a dig-
labeled probe, 5’-ACAGACACCGTCCTCACCACCC-
GGGACTTGTACCCGGGACGGGTG-3’.T h es e c t i o n s
were detected with immunoalkaline phosphatase and
developed with BCIP/NBT.
Statistical analysis
The clinical data were extracted from the medical
records. Two-sample comparisons were done with the
Fischer’s test for categorical data and the Mann-Whit-
ney test for continuous data. 2-year overall survival (OS)
rate and disease-free survival (DFS) rate analyses were
done with the Kaplan-Meier method.
Results
EBER1 suppressed transcription of p21
cip1/waf1
EBER1-expressing plasmids (p9362-EBER) or control
plasmids (p9362) were transfected into KMH2 and L428
cells. Four stable cell lines were established: EBER1
+
KMH2 (KE), EBER1
+L428 (LE), p9362-KMH2 (K9), and
p9362-L428 (L9). As shown in Fig 1, the expression of
EBER1 in KE was similar to that of an EBV-infected
KMH2 cell line (K-EBV). The expression of EBER1 in
LE was higher than that of KE but lower than that of an
EBV-infected lymphoblastoid cell line (LCL).
Microarrays were used to screen for EBER1-induced
changes, and the changes were measured by the z-score
Figure 1 Northern blotting demonstrated EBER1 expression in KE and LE. The expression of EBER1 was measured by Northern blotting in
the KMH2 cell line (K), an EBV-infected KMH2 cell line (K-EBV), KE, LE, and an EBV-infected lymphoblastoid cell line (LCL). The expression of EBER1
in KE was similar to that of K-EBV. The expression of EBER1 in LE was higher than that of KE, but lower than that of LCL.
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by EBER1, and a negative score was given if a decrease
was induced by EBER1. A gene was therefore given a z-
score, ZK, for the changes between KE & K9, and a second
z-score, ZL, for the changes between LE & L9.
Because true physiologic actions of EBER1 should be
induced in both KE and LE cell lines, ZK and ZL should be
concordantly increased or decreased. For facilitating the
identification of such concordant changes, the z-scores, ZK
&Z L, were multiplied. The genes were then listed accord-
ing to the values of ZK *ZL. The top 10 genes with the lar-
gest concordant decrease or increase are listed in Table 1.
Among these top-ranking genes in Table 1, EGR1 and
p21
cip1/waf1 appeared to be functionally related, because
EGR1 can activate p21
cip1/waf1 transcription [18,19].
Transcription factors of p21
cip1/waf1, such as EGR1 &STAT1,
were also decreased by EBER1
In Fig 2A, the transcripts of p21
cip1/waf1-related genes
were analyzed in details, such as EGR1, STAT1 [20], p53
[21,22], and cyclins. Significantly, EGR1 and STAT1
were decreased by EBER1 across all probe sets that were
used in the Affymetrix chip to monitor a single gene. In
contrast, p53, a physiologic regulator of p21
cip1/waf1, and
cyclins, the physiologic targets of p21
cip1/waf1,d i dn o t
have consistent changes. These preliminary observations
indicated that EBER1-induced p21
cip1/waf1 suppression
was related to EGR1 and STAT1, but not necessarily to
p53, and did not lead to consistent changes in cyclins.
EBER1 suppressed p21
cip1/waf1 transcription
To confirm the microarray data and to exclude the possi-
bility of EBER1-induced changes in alternative splicing
patterns, we used RT-PCR for a semi-quantitative assess-
ment of all 8 splicing variants of p21
cip1/waf1.V a r i a n t1
was always the dominant form (Fig 2B). Real-time RT-
PCR (Fig 2C) further showed the dCT (mean +/- SD)
was 6.2 +/- 0.2 for K9, 8.7 +/- 0.4 for KE, 11.5 +/- 0.2 for
L9, and 13.0 +/- 0.4 for LE. Pairwise comparisons
between the cell lines were all significant at p <0 . 0 0 1b y
the t-test. Thus K9 had more p21
cip1/waf1 transcripts than
L9, and the presence of EBER1 decreased p21
cip1/waf1 in
both cell lines. The relative levels, K9>KE>L9>LE, were
consistent with the results from microarrays. Together,
these data showed that EBER1 suppressed p21
cip1/waf1
transcription without altering alternative splicing.
EBER1 suppressed the expressions of p21
cip1/waf1, EGR1,
STAT1, & p53
Western blotting was used for confirming the microar-
ray data at the levels of protein expression. In Fig 3A,
EBER1 decreased p21
cip1/waf1 in both KE and LE cell
Table 1 Genes concordantly down- or up-regulated by EBER1 in KMH2 & L428
Unigene Gene Title K9 KE L9 LE ZK ZL ZK*ZL
Top 10 down-regulated genes
Hs.326035 Early growth response 1 379 110 3992 437 -3.8 -6.1 23.2
Hs.370771 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 2260 1164 613 18 -2.5 -7.6 19.4
Hs.440366 Similar to sirtuin 5 isoform 2; sir2-like 5 340 93 1416 201 -3.9 -4.7 18.5
Hs.56382 Hexamthylene bis-acetamide inducible 2 208 54 316 24 -3.4 -5.3 18.1
Hs.3210 Renin 483 21 93 20 -7.8 -2.2 17.0
Hs.143757 Similar to zinc finger protein 111 450 123 258 42 -4.1 -3.7 15.1
Hs.199877 Copine IV 454 154 2186 449 -3.6 -4.1 14.7
Hs.501778 Tripartite motif-containing 22 1200 606 554 47 -2.7 -5.4 14.5
Hs.349110 Hepatocyte growth factor-like 184 50 317 50 -3.2 -3.8 12.4
Hs.129867 Calcium and integrin binding family member 2 150 52 213 15 -2.6 -4.8 12.2
Top 10 up-regulated genes
Hs.292788 Homo sapiens, clone IMAGE:5189562, mRNA 10 167 22 180 3.7 4.9 18.1
Hs.147434 TRAF3 interacting protein 3 175 605 446 3676 2.8 6.4 17.9
Hs.550344 CDNA FLJ32691 fis, clone TESTI2000221 25 185 66 250 3.9 3.9 15.4
Hs.163914 Hypothetical protein DKFZp313G1735 14 138 15 160 3.2 4.6 14.8
Hs.154510 Chr 2 open reading frame 4///Carbonyl reductase 3 15 97 11 244 2.3 6.2 14.2
Hs.247831 Myosin light chain 2, precursor lymphocyte-specific 77 384 82 308 3.5 4.0 14.0
Hs.268939 Matrin 3 254 698 18 219 2.3 5.8 13.1
Hs.515011 SMAD specific E3 ubiquitin protein ligase 2 67 232 114 580 2.7 4.8 13.0
Hs.512709 Troponin I type 3 (cardiac) 34 206 31 114 3.9 3.1 12.1
Hs.530863 CASK interacting protein 1 19 126 35 162 2.9 4.0 11.8
From left to right, the columns show the UniGene number, the gene title, the gene symbol, the levels of the transcripts in K9, KE, L9, and LE, the z-score (ZK)f o r
the comparison between K9 & KE, the z-score (ZL) between L9 & LE, and the product of ZK *ZL.
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the expression of p21
cip1/waf1 protein was not sup-
pressed. Thus the suppression on p21
cip1/waf1 was not a
nonspecific effect of RNA, but required the specific
sequence of EBER1.
In Fig 3B, the positive regulators of p21
cip1/waf1 tran-
scription, such as EGR1 & STAT1, were decreased by
EBER1. Unexpected from the array data, p53, another
positive regulator of p21
cip1/waf1 transcription, was also
decreased in both KE & LE cell lines.
Because p21
cip1/waf1 transcription was reported to be
up-regulated by histone acetylation [23,24], Western
blotting for the histone deacetylase, SirT5, was per-
formed. SirT5 was decreased in the KE cell line, but
increased in the LE cell line. Further experiments are
thus necessary for clarifying the role of SirT5.
EBER1-induced p21
cip1/waf1 suppression was associated
with decreased cyclin D2, but did not change the cell
cycle distributions
Because p21
cip1/waf1 may arrest the cell cycle at the G1/S
transition, we investigated the effect of suppressed
p21
cip1/waf1 on the cell cycle. We found decreased cyclin
D2 in KE & LE, but not other CDKs & cyclins (Fig 3C).
Cyclin D2 normally peaks at the late G1 phase and pro-
motes the G1/S transition. The simultaneous decrease
of cyclin D2 and p21
cip1/waf1 may have opposite effects
on the G1/S transition, resulting in no net changes in
the cell cycle distributions (Fig 3D).
EBER1 conferred resistance to apoptosis induced
by TSA & MG115
The histone deacetylase inhibitor TSA increases p21
cip1/
waf1 transcription [24], and the proteasome inhibitor
MG115 increases p21
cip1/waf1 by abolishing protein
degradation [25]. Both have been used extensively in
treatment of lymphoma, because of their ability to
induce apoptosis [26,27].
The susceptibility of K9, KE, L9, and LE to drug-
induced apoptosis was tested. Triplicate measurements
by flow cytometry showed that the percentages of viable
cells (mean +/- SD) after TSA treatment (Fig 4A) were
91.1 +/- 2.0 for K9, 93.0 +/- 4.9 for KE, 25.2 +/- 13.6
for L9, and 76.9 +/- 5.3 for LE. L9 and LE had less
viable cells than K9 and KE. Significantly, L9 was even
less viable than LE (p = 0.04, paired t-test). Similarly,
the percentages of viable cells (mean +/- SD) after
MG115 treatment (Fig 4B) were 55.1 +/- 11.7 for K9,
76.9 +/- 7.3 for KE, 95.9 +/- 6.2 for L9, and 95.3 +/- 2.6
for LE. K9 and KE had less viable cells than L9 and LE.
Significantly, K9 was even less viable than KE (p =0 . 0 3 ,
paired t-test). Thus, L9 was more sensitive to TSA than
LE (Fig 4A), and K9 was more sensitive to MG115 than
KE (Fig 4B). The differential sensitivities implied that
Figure 2 EBER1 decreased p21
cip1/waf1 transcription in HL cell lines. 2A: Transcript profiles of p21
cip1/waf1-related genes. The z-scores, ZK in
white and ZL in black, were plotted for the following genes: 1) p21
cip1/waf1 & its regulators: EGR1 and STAT1, 2) cell cycle-related genes: p53 and
cyclins. Note that the Affymetrix chip used multiple sets of probes to monitor a single gene, but only EGR1 and STAT1 showed consistent
decreases across all probe sets. 2B: Eight splicing variants of p21
cip1/waf1 have been reported: variant 1, variant 2, Alternative-a (Alt-a), Alternative-
a’ (Alt-a’), Alternative-b (Alt-b), Alternative-c (Alt-c), B, and C. EBER1 did not change the splicing patterns, as RT-PCR showed that variant 1 was
always the dominant form for K9, KE, L9, and LE. X-axis: p21 variants; Y-axis: proportions of the variants. Only the major variants, variant 1, variant
2, B, and Alt-a were shown. The others variants were all less than 1%. 2C: Representative real-time RT-PCRs for p21
cip1/waf1 were shown. X-axis:
cDNA amount; Y-axis: dCT (the threshold cycle of p21
cip1/waf1 minus that of actin). Triplicate measurements were taken at each one of 4 cDNA
concentrations. The dCT (mean +/- SD) was 6.2 +/- 0.2 for K9, 8.7 +/- 0.4 for KE, 11.5 +/- 0.2 for L9, and 13.0 +/- 0.4 for LE.
Liu et al. Molecular Cancer 2010, 9:32
http://www.molecular-cancer.com/content/9/1/32
Page 6 of 12intrinsic properties of the cell lines could have caused
L9/LE to be more sensitive to TSA than K9/KE, and
K9/KE to be more sensitive to MG115 than L9/LE.
ELISA was used to measure the induction of p21
cip1/waf1
after drug treatments. The increase (mean +/- SD, tripli-
cate measurements) after TSA treatment (Fig 4C) was 3.0
+/- 0.7 fold in K9 cells, 2.6 +/- 1.0 fold in KE cells, 9.5 +/-
1 . 9f o l di nL 9c e l l s ,a n d4 . 0+ / -1 . 6f o l di nL Ec e l l s .L 9
and LE had more induction of p21
cip1/waf1 than K9 and
KE, and significantly L9 showed higher induction of
p21
cip1/waf1 than LE (p = 0.02, paired t-test). Similarly, the
increase (mean +/- SD, triplicate measurements) after
MG115 treatment (Fig 4D) was 3.7 +/- 0.4 fold in K9 cells,
2.1 +/- 0.5 fold in KE cells, 1.0 +/- 0.1 fold in L9 cells, and
0.8 +/- 0.1 fold in LE cells. K9 and KE had more induction
of p21
cip1/waf1 than L9 and LE, and significantly K9 showed
higher induction of p21
cip1/waf1than KE (p = 0.01, paired t-
test). Thus, consistent with the data on apoptosis, L9 cells
had the most significant increase of p21
cip1/waf1 under
TSA treatment (Fig 4C) and K9 cells had the most
Figure 3 EBER1 suppressed p21
cip1/waf1 without changes in cell cycle distributions.3 A :EBER1 suppressed p21
cip1/waf1. Left panel: EBER1
decreased p21
cip1/waf1 in KE and LE, although overloading was necessary to show the much weaker levels of p21
cip1/waf1 in L9 & LE. Right panel:
EBER1 but not antisense EBER1 suppressed p21
cip1/waf1. 3B: EBER1 suppressed EGR1, STAT1, and p53, but had no consistent effects on SirT5. The
doublets of STAT1 were due to isoforms. 3C: Western blotting showed decreased cyclin D2 in KE & LE, but no changes in the levels of CDKs or
other cyclins. 3D: Cell cycle distributions of K9 (dash) and KE (solid) on the left, L9 (dash) and LE (solid) on the right. There were no detectable
differences in the cell cycle distributions between KE & K9, or LE & L9. The Y-axis is the number of cells. The X-axis is the intensity of propidium
iodide (PI) on a linear scale from zero to 1000. The first peak at around 250 had diploid DNA content (2N) and was the peak of the G0/G1
phase. The second peak at around 500 had quadruploid DNA content (4N) and was the peak of the G2/M phase. Between these 2 peaks, cells
were in S phase.
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Page 7 of 12significant increase of p21
cip1/waf1 under MG115 treatment
(Fig 4D).
The effects of TSA and MG115 on cell growth were
measured. Based on 4 repeats, the cell numbers at 48
hours (mean +/- SD in 10
4) after TSA treatment (Fig
4E) were 3.6 +/- 0.4 for untreated LE, 3.7 +/- 0.5 for
untreated L9, 2.4 +/- 0.1 for treated LE, and 0.7 +/- 0.1
for treated L9. Treated L9 cells grew slower than the
others (p < 0.001, one-way ANOVA). Similarly, the cell
numbers at 48 hours (mean +/- SD in 10
4) after MG115
treatment (Fig 4F) were 3.3 +/- 0.1 for untreated KE,
2.8 +/- 0.1 for untreated K9, 1.8 +/- 0.1 for treated KE,
and 0.6 +/- 0.1 for treated K9. Treated K9 cells grew
slower than the others (p < 0.001, one-way ANOVA).
Thus, L9 grew slower than LE cells when treated with
TSA (Fig 4E), whereas K9 grew slower than KE cells
when treated with MG115 (Fig 4F).
T a k e nt o g e t h e r ,t h e s ed a t aw e r ec o n s i s t e n tw i t ht h e
hypothesis that EBER1 suppressed p21
cip1/waf1 transcrip-
tion and conferred resistance to drug-induced apoptosis
in these model systems.
EBV
+ Hodgkin lymphoma is associated with suppression
of p21
cip1/waf1 and a worse prognosis
Ninety-four HLs, including 68 EBV
- and 26 EBV
+ cases,
were used for the assessment of the clinical significance
of p21
cip1/waf1 suppression (Fig 5 and Table 2).
Immunohistochemical stains were performed for p21
cip1/
waf1 (Fig 5A), active caspase 3 as an apoptotic marker
[28], and Ki67 as a proliferation marker. The percentages
of Reed-Sternberg cells that were positive for p21
cip1/waf1
were determined, and the median values for the EBV
+
and the EBV
- groups were listed in Table 2. Compared
with the EBV
- group, the EBV
+ group was slightly more
likely to present at a later stage and a higher LDH level
(p = 0.09 and 0.08, respectively). The EBV
+ group
expressed significantly less p21
cip1/waf1 (44% vs. 76%, p <
0.001) and active caspase 3 (4% vs.2 2 % ,p < 0.001), but
had a similar amount of Ki67 (52% vs. 54%, p = 0.80).
The 2-year OS rate (98% vs.6 8 % ,p < 0.001, Fig 5B)
and 2-year DFS rate (77% vs. 45%, p = 0.002, Fig 5C)
were both better in the EBV
- g r o u pt h a ni nt h eE B V
+
group. In our series, there were 6 primary refractory
cases in the EBV
- group and 10 primary refractory cases
in the EBV
+ group (9% vs. 38%, p =0 . 0 0 2 ) .T h em u c h
higher frequency of primary refractory cases in the EBV
+ group was the main reason for the worse prognosis.
Although EBV
+ and EBV
- HLs differed in several para-
meters and the clinical observations did not establish a
casual link, these findings were consistent with the
hypothesis that suppression of p21
cip1/waf1 allowed the
tumor cells in EBV
+ HLs to escape spontaneous apopto-
sis or to resist drug-induced apoptosis, resulting in a
more aggressive clinical behavior.
Figure 4 EBER1 conferred resistance to apoptosis induced by TSA & MG115. 4A & 4B: Left panel: Apoptosis induced by 0.5 μM TSA (4A) or
0.4 μM MG115 (4B) for 2 days was measured by flow cytometry. The X-axis is Annexin-V (AV) and the Y-axis is propidium iodide (PI). Both the X
and Y-axes are in log scale from 10
0 to 10
4. Green: AV
-/PI
- viable cells. Blue: AV
+/PI
dim apoptotic cells. Red: AV
+/PI
bright dead cells. Right panel:
The percentages of viable cells after treatments were measured. (Y-axis: percentage of viable cells; X-axis: cell lines). Note that L9 was the most
sensitive cell line after TSA treatment (4A), and K9 was the most sensitive cell line after MG115 treatment (4B). 4C & 4D: Induction of p21
cip1/waf1
by 0.5 μM TSA (4C) or by 0.4 μM MG115 (4D) was measured with ELISA. (Y-axis: p21
cip1/waf1 of treated cell lines divided by that of untreated cell
lines; X-axis: cell lines). Note that L9 showed the highest induction after TSA treatment and K9 showed the highest induction after MG115
treatment. 4E & 4F: After treatment with 0.5 μM TSA, L9 cells grew slower than LE cells(4E), and after treatment with 0.4 μM MG115, K9 cells
grew slower than KE cells (4F). (Y-axis: cell numbers in 10
4; X-axis: duration of culture in days; UNT: untreated).
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Page 8 of 12An anti-apoptotic model for EBER1-induced p21
cip1/waf1
suppression
To integrate our data, we present an anti-apoptotic
model (Fig 5D), in which EBER1 suppresses p21
cip1/waf1
transcription indirectly through EGR1, and STAT1. In
addition, EBER1 might suppress p21
cip1/waf1 through the
wild-type p53 in KE, but not the mutant-type p53 in LE
[29,30]. Since the binding sites on the p21
cip1/waf1 pro-
moter for EGR1 [18,19] and STAT1 [20] and p53
[21,22] are already known, further studies are necessary
to reveal how EBER1 suppresses p53, EGR1, and
STAT1, and whether or not post-transcriptional regula-
tions of p21
cip1/waf1 are also involved.
Discussion
We found that EBER1 suppresses p21
cip1/waf1 transcrip-
tion and inhibits drug-induced apoptosis, but does not
change the cyclins [31] except for cyclin D2. The anti-
apoptotic activity of EBER1 could be critical in the res-
cue of HL cells from apoptosis. These cells have
crippled immunoglobulin genes and should have under-
gone apoptosis in the germinal center [32]. The
Figure 5 EBV Hodgkin lymphomas is associated with suppression of p21
cip1/waf1 and a worse prognosis. 5A: Immunohistochemistry of
p21
cip1/waf1. Upper panel from left to right: K9, L9, and an EBV
— HL were positive for p21
cip1/waf1. Lower panel from left to right: KE, LE, and an
EBV
+ HL were negative for p21
cip1/waf1. Immunoperoxidase stains on formalin-fixed, paraffin-embedded cell blocks or tissue sections. 5B: The EBV
+ group also had a worse 2-year OS rate than did the EBV
— group (68% vs. 98%, p < 0.001 by logrank test). 5C: The EBV
+ group had a worse 2-
year DFS rate than did the EBV
— group (45% vs. 77%, p = 0.002 by logrank test). 5D: EBER1 inhibits apoptosis and maintains latency through
p21
cip1/waf1 suppression (Arrow: increase; Bar: decrease). Our data are consistent with the model that EBER1 could inhibit p21
cip1/waf1 transcription
through EGR1, STAT1, or p53. The inhibition of p21
cip1/waf1 is associated with resistance to drug-induced apoptosis. Because p21
cip1/waf1 is
necessary for lytic induction by EBV-encoded ZTA [36,37], EBER1 may be critical for the maintenance of the latency phase as well. Since the
binding sites on the p21
cip1/waf1 promoter for EGR1 [18,19], STAT1 [20], and p53 [21,22] are already known, further studies are necessary to reveal
how EBER1 suppresses p53, EGR1, and STAT1, and whether or not post-transcriptional regulations of p21
cip1/waf1 are also involved.
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Page 9 of 12increased resistance to drug-induced apoptosis offers a
possible explanation for the worse clinical behavior of
EBV
+ HLs [1].
Although most HLs respond to chemotherapy, about
25% of HLs are refractory or relapse after an initial
response [1]. For these cases, it is important to identify
prognostic factors, such as the sites and extent of
relapse, and to adjust treatment accordingly. Apart from
these obvious clinical predictors, biological predictors,
such as suppression of p21
cip1/waf1, should be useful. In
fact, the clinical usefulness of p21
cip1/waf1 as a prognostic
factor has been reported repeatedly for other tumors
[33], and our data suggested possible use of p21
cip1/waf1
as a prognostic factor in EBV
+ HL.
In our study, we have used TSA, a histone deacetylase
inhibitor, and MG115, a proteasome inhibitor, to test
the effect of EBER1 on drug-induced apoptosis in HL
cell lines, because similar drugs are currently being eval-
uated for clinical usages. Bortezomib is a proteasome
inhibitor found to cause cell cycle arrest and to induce
apoptosis in HL cell lines. However, in a pilot study, the
drug demonstrated minimal activity in relapsed and
refractory HLs [26]. Similar to the conclusion of this
pilot study, our data imply that treatment with protea-
some inhibitors in EBV
+ refractory/relapsed HLs is likely
to be ineffective. Vorinostat is a histone deacetylase
inhibitor, which was found to suppress p21
cip1/waf1,
cause cell cycle arrest, and induce apoptosis in HL cell
lines [27]. Because we have compared only EBER1
+ and
EBER1
- HL cell lines, whereas the Reed-Sternberg cells
in EBV
+ HLs also express EBNA1 and LMPs, it would
be interesting to see whether these drugs are effective in
EBV
+ HLs in future clinical trials.
From the perspective of tumor biology, there are 3
subtypes of latency in EBV-infected tumor cells. EBV
+
HL is typical of type II latency, and only a limited set of
virus-associated genes is expressed. These genes include
EBNA1, LMP1 &LMP2,a n dEBERs. EBNA1 keeps the
viral genome in an episomal form, LMP1 transmits
CD40-like signals to compensate for the lack of B-cell
receptors [34], and LMP2A is a B-cell receptor mimic
that is essential for survival [35]. Because EBER1 may
suppress p21
cip1/waf1 transcription, and p21
cip1/waf1 is
necessary for lytic induction by EBV-encoded ZTA
[36,37], EBER1 may be critical for the maintenance of
the latency phase.
To integrate the data on apoptosis, drug-resistance,
and maintenance of the latency phase, we have pre-
sented a model of EBER1-induced p21
cip1/waf1 suppres-
sion through EGR1, and STAT1 (Fig 5D). Other genes
in Table 1 might be related to this model too. Sir-2-like
5 (SirT5) is a histone deacetylase that could suppress
p21
cip1/waf1 transcription [23,24]. HEXIM2, a double-
stranded RNA-binding protein [38], and MATR3, which
processes double-stranded RNAs [39], could have inter-
acted with EBER1. Finally, TRIM22 is important for
antiviral defense [40].
In addition to HL, Burkitt’s lymphoma and post-trans-
plantational lymphoproliferative disorder are also EBV-
associated B-cell lymphomas that share a similar patho-
genetic mechanism, in which EBV infection is important
in the immortalization and transformation of B cells. In
experimental conditions, EBV infection of primary B
cells leads to p21
cip/waf1suppression and overrides geno-
toxin-induced G1 arrest [41]. These EBV-infected pri-
mary B cells are in type III latency and the suppression
of p21
cip/waf1 is due to post-transcriptional regulation,
whereas HL is in type II latency and the suppression of
p21
cip/waf1 is regulated at the transcriptional level.
Despite of the differences, the suppression of p21
cip/waf1
appears to be a common event critical for the develop-
ment of these lymphomas.
At greater than 5*10
6 copies per cell, EBERs are the
most abundant RNAs in EBV-infected cells. Although
EBERs seem to prevent apoptosis through interacting
with PKR, the nuclear localization of EBERs and cyto-
plasmic localization of PKR make a direct interaction
unlikely [10]. Recently, EBERs were found to increase
transcription or mRNA stability of IL-10, IL-9, or IGF1
in lymphoma or carcinoma cell lines [42,43]. With
recognition of transcriptional regulation by EBERs and
other noncoding RNAs as important biological processes
[44], suppression of p21
cip/waf1 transcription deserves
Table 2 Suppression of p21
cip1/waf1 in EBV
+ Hodgkin
lymphoma is associated with a worse prognosis
EBV
- EBV
+ p
Clinical Manifestation
n 68 26
age 34 44 0.18
sex 33:35 19:7 0.04
stage, I&II 72% 50% 0.09
LDH 459 544 0.08
ABVD 70% 58% 0.32
Primary refractory 9% (6/68) 38% (10/26) 0.002
2-year OS 98% 68% <0.001
2-year DFS 77% 45% 0.002
Biological markers
p21
cip1/waf1 76% 44% <0.001
active caspase 3 22% 4% <0.001
Ki67 54% 52% 0.80
From top to bottom, the rows which show clinical manifestation are: number
of cases, median age in years, sex ratio in male: female, percentage of cases
in stages I & II, median LDH (lactate dehydrogenase, normal at 230-460 U/L),
percentage of cases initially treated with ABVD (Adriamycin, Bleomycin,
Vinblastine, & Dacarbazine), percentage of primary refractory cases, estimated
2-year overall survival rate, and 2-year disease-free survival rate. The rows
which show biological markers are: median percentage of Reed-Sternberg
cells that were positive for p21
cip1/waf1, active caspase 3, and Ki67.
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Page 10 of 12further investigations, because of the direct link with
apoptosis and the known example of artificial micro-
RNAs in regulating p21
cip/waf1 transcription [45].
Diepstra et al [46] reported a series of 412 HL patients
with a median age of 35 years. In patients older than 50
years, the five-year failure free survival was 60% in EBV
+
cases vs. 85% in EBV
- cases (p = 0.01). Our series of 94
cases had a median age of 31 years. In patients older
than 45 years, the 5-year disease free survival was 37%
in EBV
+ cases vs.7 4 %i nE B V
- cases (p = 0.02). In
patients younger than 45 years, the 5-year disease
free survival was 50% in EBV
+ cases vs. 67% in EBV
-
cases (p = 0.17). Our data and those reported by Diep-
stra et al were consistent in showing that EBV
+ HL had
a worse prognosis in the older age group.
In conclusion, EBER1 suppresses p21
cip1/waf1 transcrip-
tion and confers resistance to drug-induced apoptosis in
HL cell lines. Biologically, this anti-apoptotic activity
m i g h tb ei m p o r t a n ti nt h er e s c u eo fR e e d - S t e r n b e r g
cells and in the maintenance of the latent phase. Clini-
cally, the suppression of p21
cip1/waf1 in EBV
+ HL pre-
dicts a worse prognosis, and the possibility of increased
resistance to drug-induced apoptosis might have thera-
peutic implications.
Conclusion
The anti-apoptotic activity of EBER1 is well known. In
this study, we showed that EBER1 suppressed p21
cip1/
waf1 in HL cell lines through down-regulation of p53,
EGR1, and STAT1, and EBER1
+ HL cell lines were
more resistant to apoptosis induced by histone deacety-
lase inhibitors or proteasome inhibitors. Because these
drugs were known to act by increasing p21
cip1/waf1,t h e
anti-apoptotic activity of EBER1 was probably through
the suppression of p21
cip1/waf1. Clinically, EBV
+ HLs had
weaker expression of p21
cip1/waf1 and a worse prognosis,
which also supported a critical role of EBER1 in the res-
cue of Reed-Sternberg cells from apoptosis and in the
clinical behaviors of HLs.
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